Company Profile
Prelude Therapeutics Stock Price, News & Analysis
- Ticker:
- PRLD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.89 USD (+1.57%)
Close
Last updated: July 27, 2026
279M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, PRLD closed up 1.57% at $3.89. No new same-company headline was identified in the current news window.
Company overview
Business overview
Prelude Therapeutics is an oncology company focused on precision cancer medicines and epigenetic targets. Its strategy is to create differentiated therapies for genetically defined tumors.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Prelude sits in specialty oncology biotechnology.
Business Model Characteristics
The business depends on clinical proof, target validation, and the ability to build a durable oncology pipeline.
Position Within the Biotechnology Landscape
Prelude is a catalyst-driven oncology name whose stock is sensitive to early clinical and strategic signals.
Future catalysts
Prelude Therapeutics is heading into a more important stretch around its latest development priorities. Management's latest framing highlights Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file.... The stock is likely to react most to whether those milestones keep moving without a reset.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Prelude Therapeutics (PRLD)?
Prelude Therapeutics (PRLD) most recently closed at 3.89 USD, a +1.57% move versus the previous session.
What is the market cap of Prelude Therapeutics (PRLD)?
Prelude Therapeutics currently has a market capitalization of 279M USD on BioPharmSignal.
What does Prelude Therapeutics do?
Prelude Therapeutics is an oncology company focused on precision cancer medicines and epigenetic targets. Its strategy is to create differentiated therapies for genetically defined tumors.
On which exchange is PRLD stock listed?
Prelude Therapeutics (PRLD) is associated with NASDAQ, United States, Biopharma.
What is Prelude?
Prelude Therapeutics is heading into a more important stretch around its latest development priorities.
Which conditions is Prelude Therapeutics targeting with Prelude?
Prelude Therapeutics is associated with oncology, cancer therapeutics, genetic disease based on its company overview and current catalyst commentary.
How does Prelude Therapeutics describe recent progress with Prelude?
Prelude Therapeutics is heading into a more important stretch around its latest development priorities.
What is Therapeutics?
Prelude Therapeutics is an oncology company focused on precision cancer medicines and epigenetic targets.